Genocea Biosciences Inc
GNCA
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-3,088,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.22 |
| Beta | 0 |
| Outstanding Shares | 71,120,000 |
Return
| Return on Equity | -317.04% |
|---|---|
| Return on Assets | -101.23% |
| Return on Invested Capital | -175.92% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -11.44 |
| Enterprise Value to EBIT | 0.08 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -5.52 |
| Debt to Equity | 1.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genocea Biosciences Inc
CEO: William Clark Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on t...